Arrowhead Pharmaceuticals (ARWR) Free Cash Flow (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Free Cash Flow data on file, last reported at $81.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 81.8% year-over-year to $81.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.5 million (down 396.82% YoY) and the FY2025 annual result came in at $179.3 million, up 129.67% from the prior year.
• Free Cash Flow advanced to $81.9 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $449.8 million in Q1 2025 to a low of -$187.0 million in Q3 2023.
• A 5-year average of -$46.1 million and a median of -$101.4 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 535.44% — and 2025, when it soared 455.72%.
• Tracing ARWR's Free Cash Flow over 5 years: stood at -$114.4 million in 2022, then tumbled by 62.98% to -$186.5 million in 2023, then grew by 20.19% to -$148.8 million in 2024, then soared by 107.61% to $11.3 million in 2025, then surged by 622.47% to $81.9 million in 2026.
• The last three Free Cash Flow figures came in at $81.9 million (Q1 2026), $11.3 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.